Farzana Nazimuddin

4.8k total citations · 1 hit paper
11 papers, 958 citations indexed

About

Farzana Nazimuddin is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Farzana Nazimuddin has authored 11 papers receiving a total of 958 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Public Health, Environmental and Occupational Health and 2 papers in Molecular Biology. Recurrent topics in Farzana Nazimuddin's work include CAR-T cell therapy research (11 papers), Acute Lymphoblastic Leukemia research (6 papers) and Neuroblastoma Research and Treatments (1 paper). Farzana Nazimuddin is often cited by papers focused on CAR-T cell therapy research (11 papers), Acute Lymphoblastic Leukemia research (6 papers) and Neuroblastoma Research and Treatments (1 paper). Farzana Nazimuddin collaborates with scholars based in United States and Canada. Farzana Nazimuddin's co-authors include Simon F. Lacey, Carl H. June, J. Joseph Melenhorst, Bruce L. Levine, David L. Porter, Shannon L. Maude, Colleen Callahan, Irina Kulikovskaya, Fang Chen and Gabriela Plesa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Farzana Nazimuddin

11 papers receiving 950 citations

Hit Papers

Activity of Mesothelin-Sp... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
    2018 379 citations Gregory L. Beatty, Mark H. O’Hara et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Farzana Nazimuddin United States 9 865 276 262 234 213 11 958
Liqing Kang China 19 722 0.8× 188 0.7× 204 0.8× 246 1.1× 316 1.5× 68 944
Anthony F. Daniyan United States 12 784 0.9× 363 1.3× 237 0.9× 241 1.0× 326 1.5× 24 1.0k
Brock Lanier United States 5 1.0k 1.2× 439 1.6× 343 1.3× 241 1.0× 294 1.4× 8 1.1k
Diogo Gomes‐Silva United States 6 759 0.9× 274 1.0× 312 1.2× 180 0.8× 329 1.5× 9 857
Hejin Jia China 7 706 0.8× 223 0.8× 196 0.7× 220 0.9× 202 0.9× 11 784
Reona Sakemura United States 13 717 0.8× 261 0.9× 227 0.9× 261 1.1× 249 1.2× 54 879
Christopher Hunt Keir United States 12 613 0.7× 137 0.5× 189 0.7× 211 0.9× 326 1.5× 25 867
Junfang Yang China 15 636 0.7× 109 0.4× 225 0.9× 158 0.7× 226 1.1× 69 826
Brandon Ballard United States 10 847 1.0× 311 1.1× 259 1.0× 226 1.0× 326 1.5× 16 1.0k
Mireya Paulina Velasquez United States 15 589 0.7× 271 1.0× 156 0.6× 132 0.6× 218 1.0× 42 783

Countries citing papers authored by Farzana Nazimuddin

Since Specialization
Citations

This map shows the geographic impact of Farzana Nazimuddin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farzana Nazimuddin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farzana Nazimuddin more than expected).

Fields of papers citing papers by Farzana Nazimuddin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farzana Nazimuddin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farzana Nazimuddin. The network helps show where Farzana Nazimuddin may publish in the future.

Co-authorship network of co-authors of Farzana Nazimuddin

This figure shows the co-authorship network connecting the top 25 collaborators of Farzana Nazimuddin. A scholar is included among the top collaborators of Farzana Nazimuddin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farzana Nazimuddin. Farzana Nazimuddin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Beatty, Gregory L., Mark H. O’Hara, Simon F. Lacey, et al.. (2018). Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology. 155(1). 29–32. 379 indexed citations breakdown →
2.
Li, Amanda M., George Hucks, Amanda M. DiNofia, et al.. (2018). Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 556–556. 121 indexed citations
3.
Maude, Shannon L., George Hucks, Alix E. Seif, et al.. (2017). The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 35(15_suppl). 103–103. 79 indexed citations
4.
Maude, Shannon L., David T. Teachey, Susan R. Rheingold, et al.. (2016). Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.. Journal of Clinical Oncology. 34(15_suppl). 3011–3011. 117 indexed citations
5.
Lacey, Simon F., Jun Xu, Marco Ruella, et al.. (2016). Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR. Blood. 128(22). 281–281. 14 indexed citations
6.
Maude, Shannon L., David M. Barrett, Susan R. Rheingold, et al.. (2016). Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.. Journal of Clinical Oncology. 34(15_suppl). 3007–3007. 20 indexed citations
7.
Bhoj, Vijay, Dimitrios C. Arhontoulis, Gerald Wertheim, et al.. (2016). Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 128(3). 360–370. 192 indexed citations
8.
Ruella, Marco, David M. Barrett, Saad S. Kenderian, et al.. (2015). Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells. Journal for ImmunoTherapy of Cancer. 3(S2). 5 indexed citations
9.
Ruella, Marco, David M. Barrett, Saad S. Kenderian, et al.. (2015). Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. Blood. 126(23). 2523–2523. 9 indexed citations
10.
Ruella, Marco, David M. Barrett, Saad S. Kenderian, et al.. (2014). Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies. Blood. 124(21). 966–966. 4 indexed citations
11.
Kalos, Michael, Farzana Nazimuddin, Jeffrey Finklestein, et al.. (2013). Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19. Blood. 122(21). 163–163. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liqing Kang Breakdown of academic impact, for papers by Anthony F. Daniyan Breakdown of academic impact, for papers by Brock Lanier Breakdown of academic impact, for papers by Diogo Gomes‐Silva Breakdown of academic impact, for papers by Hejin Jia Breakdown of academic impact, for papers by Reona Sakemura Breakdown of academic impact, for papers by Christopher Hunt Keir Breakdown of academic impact, for papers by Junfang Yang Breakdown of academic impact, for papers by Brandon Ballard Breakdown of academic impact, for papers by Mireya Paulina Velasquez
Rankless by CCL
2026